These genetic features make LCC more suitable for treatment with adjuvant chemotherapy, such as 5‐fluorouracil (5‐FU), and therapies targeting the epidermal growth factor receptor (EGFR) [16]. This evidence concerns the gene EGFR and leukoencephalopathy with calcifications and cysts.